OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Microbiology and Infection is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Cefiderocol for resistant Gram negatives: linking in vitro activity with clinical effectiveness	751
Primary antifungal prophylaxis after haematopoietic stem cell transplantation: will the search for perfection become the enemy of good?	692
The interplay between Epstein-Barr virus and cytomegalovirus reactivation following allogeneic haematopoietic cell transplantation in the era of primary cytomegalovirus prophylaxis	459
Exploring the limits of interferon-γ releasing assay screening in large-scale populations	450
Measuring the impact of hospitalization for infectious diseases on the quality of life of older patients in four European countries: the AEQUI longitudinal matched cohort study (2020–2023)	429
Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation	275
The diagnostic value of serum Borrelia burgdorferi antibodies and seroconversion after Lyme neuroborreliosis, a nationwide observational study	203
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate	176
Post-acute COVID-19 syndrome: a new tsunami requiring a universal case definition	167
Optimizing Antifungal Therapies for Candida Infections: Evidence, Resistance, and Emerging Approaches	162
‘Scope and aims of ESCMID guidelines’ by Scudeller et al.	160
The importance of patient information and informed consent for unlicensed phage therapy	148
Re: Diagnostic limitations and challenges in current clinical guidelines and potential application of metagenomic sequencing to manage pulmonary invasive fungal infections in patients with haematologi	142
Large language models for antibiotic prescribing—moving the needle from ‘parlour trick’ to practical tool	140
‘Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward’ – author's response	130
Re: ‘The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France: a retrospective cohort study during the 20	112
Re: ‘Association between pertactin-producing Bordetella pertussis and fulminant pertussis in infants: a multicentre study in France, 2008–2019’ by Leroux et al.	112
A randomized trial of simultaneous versus sequential pneumococcal vaccination in elderly	109
Acute cough in outpatients: what causes it, how long does it last, and how severe is it for different viruses and bacteria?	108
Pathogen and host determinants of extrapulmonary tuberculosis among 1035 patients in Frankfurt am Main, Germany, 2008–2023	103
Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models	103
Re: what is the role of epidemiological investigations in human Campylobacter outbreaks in the One Health and whole-genome sequencing era in Denmark?	99
Re: Compromised access to antibiotics: addressing paediatric challenges in availability and responsible use	94
Assessment of BIV1-CovIran inactivated vaccine–elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern	92
Non-biomedical factors affecting antibiotic use in the community: a mixed-methods systematic review and meta-analysis	92

Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis	89
European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments (endorsed by European association of hospital pharmacists)	88
Should multiplex PCR testing be integrated into antimicrobial stewardship programs for paediatric community-acquired pneumonia in the emergency department?	86
Re: ‘Dosing and route of administration of clindamycin given in combination with rifampicin’ by Magreault et al.	85
What is the evidence base of used aggregated antibiotic resistance percentages to change empirical antibiotic treatment? A scoping review	84
Has the COVID-19 pandemic wiped out the seasonality of outpatient antibiotic use and influenza activity? A time-series analysis from 2014 to 2021	80
Acquired fluconazole resistance and genetic clustering in Diutina (Candida) catenulata from clinical samples	78
COVID-19 in special populations	76
How to: Diagnose inborn errors of intrinsic and innate immunity to viral, bacterial, mycobacterial, and fungal infections	75
Outside Front Cover	75
Myxovirus resistance protein A for discriminating between viral and bacterial lower respiratory tract infections in children – The TREND study	71
Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing	71
Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments	71
Which trial do we need? Doxycycline in combination with ceftriaxone for the treatment of community-acquired pneumonia	68
Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab	66
Optimising the Management of Invasive Candidiasis	65
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review	64
Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections	62
Unexpected natural cefiderocol resistance in Stenotrophomonas maltophilia associated to the genogroup 4 genetic background	61
Re: ‘Heightened incidence of adverse events associated with a live attenuated varicella vaccine strain that lacks critical genetic polymorphisms in ORF62’ by Kim et al.	61
Developing tailored dosing recommendations for ciprofloxacin in critically ill children using a population approach based on total and unbound concentrations	60
Kinetics of the Alethia® malaria loop-mediated isothermal amplification (LAMP) positivity during post-treatment follow-up of patients with imported malaria	60
Rectal colonization by multidrug-resistant Gram-negative bacteria and subsequent bacteraemia in haematological patients	60
Women's acceptance of two strategies for preventing respiratory syncytial virus infant bronchiolitis: maternal immunization or monoclonal antibodies for newborns	59
Scope and aims of European society of clinical microbiology and infectious diseases guidelines: a white paper	58
Community adoption of protective behaviours: before and during the COVID-19 pandemic	58
Evaluating stratified T-SPOT.TB results for diagnostic accuracy in tuberculosis disease: a retrospective cohort study with sensitivities, specificities, and predictive values	58
Effect of a multimodal prevention strategy on dialysis-associated infection events in outpatients receiving haemodialysis: The DIPS stepped wedge, cluster-randomized trial	57
Biofilm formation on endovascular aneurysm repair (EVAR) grafts—a proof of concept in vitro model	57
Which trials do we need?	56
In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection	55
Uncovering hidden transmission pathways of Klebsiella pneumoniae: is there a need to re-evaluate the necessity for toilet disinfection?	55
Steroids for viral meningitis: a foe or a friend?	55
Comparing large language models for antibiotic prescribing in different clinical scenarios: which performs better?	55